Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.
Standard
Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. / Müller, Volkmar; Alix-Panabières, Catherine; Pantel, Klaus.
In: EUR J CANCER, Vol. 46, No. 7, 7, 2010, p. 1189-1197.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.
AU - Müller, Volkmar
AU - Alix-Panabières, Catherine
AU - Pantel, Klaus
PY - 2010
Y1 - 2010
N2 - Tumor cell dissemination appears even in patients with small solid tumors, and bone marrow (BM) is a common homing organ for disseminated tumor cells (DTC) derived from various types of primary epithelial tumors. Tumor cells are frequently detected in the BM of cancer patients without any clinical or even histopathological signs of overt metastases. It is crucial, however, to improve and standardize methods for the detection of DTC. The characterization of DTC has shed new light on the process underlying early tumor cell dissemination and metastatic progression in cancer patients. Characterization of DTC should help to identify novel targets for biological therapies aimed at preventing metastatic relapse and to monitor the efficacy of these therapies. Evidence has emerged that the detection of DTC and circulating tumor cells (CTC) in blood may provide important prognostic information and, in addition, might help to monitor the efficacy of therapy. In this article, we summarize the clinical background and the technical aspects of current methods used for the detection and characterization of DTC in BM and CTC in blood, with a special focus on breast cancer.
AB - Tumor cell dissemination appears even in patients with small solid tumors, and bone marrow (BM) is a common homing organ for disseminated tumor cells (DTC) derived from various types of primary epithelial tumors. Tumor cells are frequently detected in the BM of cancer patients without any clinical or even histopathological signs of overt metastases. It is crucial, however, to improve and standardize methods for the detection of DTC. The characterization of DTC has shed new light on the process underlying early tumor cell dissemination and metastatic progression in cancer patients. Characterization of DTC should help to identify novel targets for biological therapies aimed at preventing metastatic relapse and to monitor the efficacy of these therapies. Evidence has emerged that the detection of DTC and circulating tumor cells (CTC) in blood may provide important prognostic information and, in addition, might help to monitor the efficacy of therapy. In this article, we summarize the clinical background and the technical aspects of current methods used for the detection and characterization of DTC in BM and CTC in blood, with a special focus on breast cancer.
M3 - SCORING: Zeitschriftenaufsatz
VL - 46
SP - 1189
EP - 1197
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
IS - 7
M1 - 7
ER -
